Table 2 Genetic causal effect of metformin use on potential mediators
From: Genetic effect of metformin use on risk of cancers: evidence from Mendelian randomization analysis
Potential mediators | GWAS identifier/reference | Beta1 | Lo_95CI | Up_95CI | P1_value |
|---|---|---|---|---|---|
BMI | ebi-a-GCST006802 [45] |  − 4.00E−01 |  − 1.51E+00 | 7.10E−01 | 4.80E−01 |
Weight | ukb-b-11842 |  − 1.72E−01 |  − 2.02E+00 | 1.68E+00 | 8.55E−01 |
Waist circumference | ieu-a-67 [46] | 5.12E−01 |  − 1.70E+00 | 2.73E+00 | 6.50E−01 |
ASATV | ebi-a-GCST90016672 [47] |  − 2.40E−01 |  − 2.56E+00 | 2.08E+00 | 8.40E−01 |
VATV | ebi-a-GCST90016671 [47] | 2.41E−01 |  − 1.61E+00 | 2.09E+00 | 7.99E−01 |
Whole body fat-free mass | ukb-b-13354 |  − 6.68E−02 |  − 1.32E+00 | 1.19E+00 | 9.17E−01 |
Body fat percentage | ukb-b-8909 |  − 1.82E−01 |  − 1.45E+00 | 1.08E+00 | 7.78E−01 |
WBC | ebi-a-GCST004610 [48] |  − 1.21E−01 |  − 1.05E+00 | 8.11E−01 | 7.99E−01 |
CRP | ieu-b-4764 |  − 1.99E−01 |  − 1.35E+00 | 9.52E−01 | 7.35E−01 |
HDL cholesterol | ieu-b-109 [49] |  − 2.38E+00 |  − 4.40E+00 |  − 3.62E−01 | 2.08E−02* |
LDL cholesterol | ieu-b-5089 |  − 2.37E+00 |  − 3.21E+00 |  − 1.54E+00 | 2.38E−08* |
Total cholesterol | ieu-a-301 [50] |  − 6.69E−01 |  − 3.02E+00 | 1.68E+00 | 5.77E−01 |
SHBG | ebi-a-GCST90012111 [51] |  − 1.50E+00 |  − 2.08E+00 |  − 9.24E−01 | 3.57E−07* |
Total testosterone | ebi-a-GCST90012114 [51] |  − 6.04E−01 |  − 9.99E−01 |  − 2.08E−01 | 2.76E−03* |
Bioavailable testosterone | ebi-a-GCST90012102 [51] | 9.28E−01 | 3.35E−01 | 1.52E+00 | 2.15E−03* |
Estradiol levels | ebi-a-GCST90012105 [51] |  − 1.23E−01 |  − 2.32E−01 |  − 1.31E−02 | 2.82E−02* |
Fasting insulin | ebi-a-GCST90002238 [52] |  − 3.85E−01 |  − 1.34E+00 | 5.68E−01 | 4.28E−01 |
Fasting glucose | ebi-a-GCST005186 [53] | 2.65E+00 | 1.06E+00 | 4.23E+00 | 1.06E−03* |
HbA1c | ieu-b-104 [54] |  − 3.96E−01 |  − 9.88E−01 | 1.97E−01 | 1.90E−01 |
Telomere length | ieu-b-4879 |  − 6.25E−03 |  − 4.43E−01 | 4.30E−01 | 9.78E−01 |